ArticleBreast cancer : basic and clinical research2016

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.

Chris Twelves et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.